kallidin, des-arg(10)- has been researched along with anatibant in 1 studies
| Studies (kallidin, des-arg(10)-) | Trials (kallidin, des-arg(10)-) | Recent Studies (post-2010) (kallidin, des-arg(10)-) | Studies (anatibant) | Trials (anatibant) | Recent Studies (post-2010) (anatibant) |
|---|---|---|---|---|---|
| 80 | 4 | 17 | 32 | 2 | 2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adam, A; Bawolak, MT; Fortin, JP; Marceau, F; Vogel, LK | 1 |
1 other study(ies) available for kallidin, des-arg(10)- and anatibant
| Article | Year |
|---|---|
The bradykinin B2 receptor antagonist icatibant (Hoe 140) blocks aminopeptidase N at micromolar concentrations: off-target alterations of signaling mediated by the bradykinin B1 and angiotensin receptors.
Topics: Angiotensin II; Angiotensin III; Aniline Compounds; Animals; Aorta; Bradykinin; Bradykinin B2 Receptor Antagonists; CD13 Antigens; Dose-Response Relationship, Drug; In Vitro Techniques; Kallidin; Kinetics; Protease Inhibitors; Quinolines; Rabbits; Receptor, Bradykinin B1; Receptor, Bradykinin B2; Receptors, Angiotensin; Recombinant Proteins; Signal Transduction; Vasoconstriction; Vasoconstrictor Agents | 2006 |